Modified Buzhong Yiqi decoction for myasthenia gravis

Jiang, Xiaotao; Chen, Guo-Ming; Huang, Jiahua; Xie, Linling; Shen, Dan‐Ting; Jiang, Kailin; Xu, Haowen

doi:10.1097/md.0000000000013677

Cited by 12 publications

(13 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the prescription, Radix Astragali seu Hedysari is the sovereign medicinal that invigorates Qi , Radix Ginseng is the minister medicinal that powerfully tonifies the primordial Qi , nourishes the lung, and invigorates the spleen, Rhizoma Atractylodis Macrocephalae invigorates the spleen, Radix Angelicae Sinensis regulates the blood, Pericarpium Citri Reticulatae regulates Qi , and prepared Radix Glycyrrhiza helps Radix Ginseng and Radix Astragali seu Hedysari rectify Qi ; Rhizoma Cimicifugae and Radix Bupleuri have the function of eliminating pathogens and raising the clear yang. The whole formula supplements and clears in that it not only tonifies the middle and replenishes Qi , but also unblocks [13–16].…”

Section: Introductionmentioning

confidence: 99%

Treatment of hospital-acquired pneumonia with multi-drug resistant organism by Buzhong Yiqi decoction based on Fuzheng Quxie classical prescription: study protocol for a randomized controlled trial

Deng

Chen

Jia

et al. 2019

Trials

View full text Add to dashboard Cite

BackgroundDrug resistance in China is becoming a more and more serious issue. Infection by drug-resistant bacteria has become a major disease that seriously threatens the health of Chinese people and affects national medical finance. Therefore, it is of great scientific and clinical significance to actively carry out research on the prevention and treatment of infections by multi-drug resistant organisms (MDRO). Previous studies by the authors suggested that patients with hospital-acquired pneumonia caused by MDRO mostly showed the pathological state of “insufficient healthy Qi and internal accumulation of pathogenic Qi” and “acute deficiency syndrome” mainly characterized by Qi deficiency. Buzhong Yiqi decoction is a famous classic prescription in traditional Chinese medicine (TCM) for treating internal damage fever. This study intends to provide an evidence-based rationale for Buzhong Yiqi decoction in treating MDRO hospital-acquired pneumonia by conducting a multi-center randomized controlled clinical study.Methods/designThis study is designed to be a multi-center randomized controlled study in which patients are assigned randomly into control (standard therapy) and trial (standard therapy plus Buzhong Yiqi decoction) groups. The patients will be selected from the emergency department and the ICU inpatient department of five study sites and will all be diagnosed with MDRO hospital-acquired pneumonia and meet the inclusion criteria. Forty patients are to be enrolled in each study site, resulting in a total of 200 patients in the study. The treatment course is 28 days.DiscussionIn this study: (1) the theory of “acute Qi deficiency” in MDRO hospital-acquired pneumonia is put forward for the first time, and the basic theories of TCM are further improved; (2) a multi-center randomized controlled clinical study will be performed for the first time with Buzhong Yiqi decoction, the classic prescription for reinforcing healthy Qi and eliminating pathogenic Qi, providing a reliable evidence-based rationale for the treatment of MDRO pulmonary infection with TCM; (3) the clinical application and modern disease spectrum of Buzhong Yiqi decoction is expanded, and the scientific notion of “treating different diseases with the same method” is enriched further.Trial registrationChina Clinical Trial Registry, ChiCTR1900022429. Registered on April 11, 2019. http://www.chictr.org.cn/listbycreater.aspx.

show abstract

Section: Introductionmentioning

confidence: 99%

Treatment of hospital-acquired pneumonia with multi-drug resistant organism by Buzhong Yiqi decoction based on Fuzheng Quxie classical prescription: study protocol for a randomized controlled trial

Deng

Chen

Jia

et al. 2019

Trials

View full text Add to dashboard Cite

show abstract

“…Buzhong Yiqi Decoction is a famous prescription in ancient China that has been used for more than 700 years in China and has been widely used in the sinking of qi due to qi deficiency. [ 24 , 25 ] The composition of Buzhong Yiqi Decoction is Radix Astragali (Zhi Huang Qi), ginseng (Ren Shen), angelica sinensis (Dang Gui), tangerine peel (Chen Pi), cimicifuga foetida (Sheng Ma), bupleurum (Chai Hu), fried atractylodes (Chao Bai Zhu), and baked licorice (Zhi Gan Cao). The astragalus (Huang Qi) in this prescription could strengthen the center and benefit vital energy, raise yang and lift prolapsed zang-fu organs; Ginseng (Ren Shen), atractylodes (Bai Zhu), and glycyrrhiza (Gan Cao) could reinforce the spleen to replenish qi; tangerine peel (Chen Pi) could regulate the functional activities of qi; angelica sinensis (Dang Gui) could enrich the blood and invigorate the circulation of blood; cimicifuga foetida (Sheng Ma) and bupleurum (Chai Hu) could ascend up the spleen qi.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of Buzhong Yiqi decoction combined with surgery for rectal prolapse

et al. 2020

View full text Add to dashboard Cite

Background: It is extremely easy for rectal prolapse to relapse with surgery alone. Clinical practice indicates that Buzhong Yiqi decoction combined with surgery has certain therapeutic advantages, while there is a lack of evidence-based medicine support. This study aimed to systematically investigate the efficacy and safety of Buzhong Yiqi decoction combined with surgery in the treatment of rectal prolapse. Methods: The English databases (PubMed, Embase, Web of Science, the Cochrane Library) and Chinese databases (China National Knowledge Infrastructure [CNKI], Wanfang, China Science and Technology Journal Database [VIP], China Biology Medicine disc) were searched by computer. In addition, Baidu Scholar and Google Scholar were searched manually. A randomized controlled clinical study of Buzhong Yiqi decoction combined with surgery in the treatment of rectal prolapse was performed from the establishment of databases to September 2020. Two investigators independently conducted data extraction and assessed the literature quality of the included studies. The Revman5.3 software was used for meta-analysis of the included literature. Results: The efficacy and safety of Buzhong Yiqi decoction combined with surgery in the treatment of rectal prolapse were evaluated in terms of efficiency, symptom score, recurrence rate, adverse reaction rate, and so on. Conclusions: Thisstudy provides reliable evidence-based support for the clinical application of Buzhong Yiqi decoction combined with surgery in the treatment of rectal prolapse. OSF Registration number: DOI: 10.17605/OSF.IO/K3PJX.

show abstract

“…A study found that using TCM combined with western medicine might improve the total effect and reduce the risk of MG relapse [ 9 ]. According to the TCM characteristic theory of “spleen governing muscle,” MG is generally diagnosed as “spleen qi deficiency syndrome” and thereby, strengthening the spleen and replenishing qi is a common therapeutic strategy of MG in TCM, which has played a positive role in clinical practice of MG [ 10 , 11 ]. Buzhong Yiqi decoction (BYD), a classical qi -supplementing formula in TCM, is the most frequently used prescription to treat MG. A study showed that BYD modulated the balance of Treg and Th17 cells in patients with MG and downregulated the serum AChR antibody level [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

Effectiveness of modified Buzhong Yiqi decoction in treating myasthenia gravis: study protocol for a series of N-of-1 trials

Weng

Chen

et al. 2022

Trials

View full text Add to dashboard Cite

Background Myasthenia gravis (MG) is an acquired autoimmune disease with high heterogeneity. The disease is chronic, relapsing repeatedly and progressive with acute exacerbation occasionally. Although the treatment of MG has developed, it is still unsatisfactory and has some unexpected side effects. Traditional Chinese medicine (TCM) has shown great potential in MG treatment, including relief of muscle weakness syndrome, improvement of patient’s quality of life, and reduction of side effects of western medicine. The purpose of this study is to evaluate the effectiveness of modified Buzhong Yiqi decoction (MBYD) as an add-on therapy for MG through a small series of N-of-1 trials. Methods Single-centre, randomized, double-blind, 3 crossover N-of-1 trials will be conducted to enroll patients with MG diagnosed as spleen-stomach deficiency syndrome or spleen-kidney deficiency syndrome in TCM. Each N-of-1 trial has 3 cycles of two 4-week periods containing the MBYD period and placebo period. The wash-out interval of 1 week is prior to switching each period. Primary outcome: quantitative myasthenia gravis (QMG). Secondary outcomes: the following scales: myasthenia gravis composite (MGC), myasthenia gravis activities of daily living profile (MG-ADL), myasthenia gravis quality of life (MG-QOL); the level of CD4+FoxP3+Treg cells and cytokines (IL-4, IL-17A, INF-γ, TGF-β) in the peripheral blood; the alterations of the composition of gut microbiota; reduction of the side effects of western medicine. Discussion Used by WinBUGS software, we will conduct a hierarchical Bayesian statistical method to analyze the efficacy of MBYD in treating MG in individuals and populations. Some confounding variables such as TCM syndrome type and potential carryover effect of TCM will be introduced into the hierarchical Bayesian statistical method to improve the sensitivity and applicability of the trials, and the use of prior available information within the analysis may improve the sensitivity of the results of a series of N-of-1 trials, from both the individual and population level to study the efficacy of TCM syndrome differentiation. We assumed that this study would reveal that MBYD is effective for MG and provide robust evidence of the efficacy of TCM to treat MG. Trial registration Chinese Clinical Trial Register, ID: ChiCTR2000040477, registration on 29 November 2020.

show abstract

Modified Buzhong Yiqi decoction for myasthenia gravis

Cited by 12 publications

References 12 publications

Treatment of hospital-acquired pneumonia with multi-drug resistant organism by Buzhong Yiqi decoction based on Fuzheng Quxie classical prescription: study protocol for a randomized controlled trial

Treatment of hospital-acquired pneumonia with multi-drug resistant organism by Buzhong Yiqi decoction based on Fuzheng Quxie classical prescription: study protocol for a randomized controlled trial

Efficacy and safety of Buzhong Yiqi decoction combined with surgery for rectal prolapse

Effectiveness of modified Buzhong Yiqi decoction in treating myasthenia gravis: study protocol for a series of N-of-1 trials

Contact Info

Product

Resources

About